Meningococcal Conjugate Vaccines Policy Update: Booster Dose Recommendations
Author:
- Committee on Infectious DiseasesCDCommittee on Infectious Diseases
- 1 December 2011
- journal article
- practice guideline
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 128 (6) , 1213-1218
Abstract
This Policy Statement was retired January 2015.: The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention and the American Academy of Pediatrics approved updated recommendations for the use of quadravalent (serogroups A, C, W-135, and Y) meningococcal conjugate vaccines (Menactra [Sanofi Pasteur, Swiftwater, PA] and Menveo [Novartis, Basel, Switzerland]) in adolescents and in people at persistent high risk of meningococcal disease. The recommendations supplement previous Advisory Committee on Immunization Practices and American Academy of Pediatrics recommendations for meningococcal vaccinations. Data were reviewed pertaining to immunogenicity in high-risk groups, bactericidal antibody persistence after immunization, current epidemiology of meningococcal disease, meningococcal conjugate vaccine effectiveness, and cost-effectiveness of different strategies for vaccination of adolescents. This review prompted the following recommendations: (1) adolescents should be routinely immunized at 11 through 12 years of age and given a booster dose at 16 years of age; (2) adolescents who received their first dose at age 13 through 15 years should receive a booster at age 16 through 18 years or up to 5 years after their first dose; (3) adolescents who receive their first dose of meningococcal conjugate vaccine at or after 16 years of age do not need a booster dose; (4) a 2-dose primary series should be administered 2 months apart for those who are at increased risk of invasive meningococcal disease because of persistent complement component (eg, C5–C9, properdin, factor H, or factor D) deficiency (9 months through 54 years of age) or functional or anatomic asplenia (2–54 years of age) and for adolescents with HIV infection; and (5) a booster dose should be given 3 years after the primary series if the primary 2-dose series was given from 2 through 6 years of age and every 5 years for persons whose 2-dose primary series or booster dose was given at 7 years of age or older who are at risk of invasive meningococcal disease because of persistent component (eg, C5–C9, properdin, factor H, or factor D) deficiency or functional or anatomic asplenia.Keywords
This publication has 16 references indexed in Scilit:
- Early Estimate of the Effectiveness of Quadrivalent Meningococcal Conjugate VaccineThe Pediatric Infectious Disease Journal, 2011
- Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescentsHuman Vaccines, 2010
- Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2–10 years of ageVaccine, 2010
- Phase I/II, Open-Label Trial of Safety and Immunogenicity of Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Human Immunodeficiency Virus-Infected AdolescentsThe Pediatric Infectious Disease Journal, 2010
- Clinical and Immunologic Risk Factors for Meningococcal C Conjugate Vaccine Failure in the United KingdomThe Journal of Infectious Diseases, 2006
- Serogroup C Meningococcal Glycoconjugate Vaccine in Adolescents: Persistence of Bactericidal Antibodies and Kinetics of the Immune Response to a Booster Vaccine More Than 3 Years after ImmunizationClinical Infectious Diseases, 2006
- Antibody Persistence 3 Years after Immunization of Adolescents with Quadrivalent Meningococcal Conjugate VaccineThe Journal of Infectious Diseases, 2006
- Prevention and Control of Meningococcal Disease: Recommendations for Use of Meningococcal Vaccines in Pediatric PatientsPediatrics, 2005
- Immune Response to Meningococcal Serogroup C Conjugate Vaccine in Asplenic IndividualsInfection and Immunity, 2004
- Meningococcal Disease Prevention and Control Strategies for Practice-Based Physicians (Addendum: Recommendations for College Students)Pediatrics, 2000